Trial Profile
A Phase II Randomized Multicentre Study Evaluating the Efficacy of Pazopanib+Best Supportive Care (BSC) Versus BSC Alone in Metastatic and/or Locally Advanced Unresectable GIST, Resistant to Imatinib and Sunitinib.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Aug 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Acronyms PAZOGIST
- 03 Dec 2021 Data was used from trials (PAZOGIST & GRID) to assess cost-effectiveness of pazopanib versus regorafenib as a third-line treatment for metastatic or unresectable gastrointestinal stromal tumors in Chinapresented at the 24th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 05 Apr 2016 Primary endpoint has been met. (Progression-free survival), as per article published in the Lancet Oncology.
- 05 Apr 2016 Results published in the Lancet Oncology